.png)
Eosinophilic esophagitis (EoE) is a chronic inflammatory condition of the esophagus that is increasingly being recognized and diagnosed. It is characterized by the presence of a high number of eosinophils, a type of white blood cell, in the esophagus. While the exact cause of EoE is not fully understood, it is believed to be related to an immune reaction to certain foods or environmental allergens.
Biologics are a class of medications that target specific proteins in the body involved in the inflammatory response. They have shown promising results in the treatment of EoE by reducing inflammation and symptoms associated with the condition. Here are 10 biologics medications that are currently being used or studied for the treatment of EoE:
- Benralizumab
- Mepolizumab
- Reslizumab
- Secukinumab
- Tralokinumab
- Rituximab
- Omalizumab
- Vedolizumab
- Ustekinumab
- Etrolizumab
These biologics work by targeting different pathways involved in the inflammatory response in EoE. They are administered either through injection or infusion and are typically reserved for individuals with moderate to severe EoE who do not respond to other treatments such as proton pump inhibitors or dietary changes.
It is important to consult with a healthcare provider to determine the most appropriate biologic medication for your specific case of EoE. While biologics have shown promising results in managing EoE symptoms, they may also have potential side effects and risks that should be carefully considered before starting treatment.